Vaishnavi Raja, PhD

ICON plc
Study Start Up Associate II
Centralized Informed Consent Team
Clinton Township, MI, USA



Dr. Raja is a highly motivated and problem solver in the field of clinical researcher with 3 years’ experience as clinical regulatory / IND coordinator / regulatory affairs, 2 years’ experience in ovarian cancer research, 9 years’ experience in biomedical research, 4 years’ experience as a teaching assistant at Wayne State University and certified SAS programmer with clinical SAS training.

In addition, Dr. Raja has excellent verbal and written communication skills resulting in 11 peer-reviewed manuscripts and abstracts. She effectively disseminated complex scientific information to health care professionals, patients, and researchers as evident in various oral and poster presentations at national and international conferences. She has mentored several undergraduate and graduate students and also served in the judging panel for multiple symposiums at Wayne State University.


• (2010-2016) PhD, Wayne State University
• (2007-2010) MS, Wayne State University
• (2002-2006) BTech, Anna University

Research Interest

Her research interest areas include: Oncology, Cell and molecular biology, Genetics, Clinical study protocol, Case report forms, Data management plan, Informed consent form, Institutional Review Board (IRB), GCP guidelines, Code of federal regulations, Clinical trials monitoring, Regulatory compliance.

Scientific Activities

• (2018), Best poster, Henry Ford Health System, Research Symposium
• (2018), AACR travel award, HFCI
• (2015), Best poster (3rd place), 6th Annual Graduate School Research day, WSU
• (2014–2015), Thomas C. Rumble University Graduate Fellowship, WSU
• (2014), Outstanding Graduate Research Assistant Award, WSU
• (2014), Best poster (3rd place), Inaugural Lipids @ Wayne Symposium, WSU
• (2013), Graduate/Postdoctoral Travel Award, Barth Syndrome Foundation
• (2013), Outstanding Graduate Teaching Assistant Award, WSU
• (2012–2013), WSU Graduate Student Professional Travel Award
• (2012), Graduate/Postdoctoral Travel Award, Barth Syndrome Foundation


1. Raja V, Greenberg ML. The functions of cardiolipin in cellular metabolism–potential modifiers of the Barth syndrome phenotype. Chem Phys Lipids. 2014; 179: 49-56. doi: 10.1016/j.chemphyslip.2013.12.009
2. Raja V, Joshi AS, Li G, Maddipati KR, Greenberg ML. Loss of cardiolipin leads to perturbation of acetyl-CoA synthesis. J Biol Chem. 2017; 292(3): 1092-1102 . doi: 10.1074/jbc.M116.753624
3. Raja V, Reynolds CA, Greenberg ML. Barth syndrome: A life-threating disorder caused by abnormal cardiolipin remodeling. J Rare Dis Res Treat. 2017; 2(2): 58-62. doi: 10.29245/2572-9411/2017/2.1087
4. Raja V, Salsaa M, Joshi AS, Li Y, van Roermund CWT, Saadat N, et al. Cardiolipin-deficient cells depends on anaplerotic pathways to ameliorate defective TCA cycle function. Biochim Biophys Acta Mol Cell Biol Lipids. 2019; 1864(5): 654-661. doi: 10.1016/j.bbalip.2019.02.001
5. Li Y, Lou W, Raja V, Yu W, Denis S, Yu W, Schmidtke MW, et al. Cardiolipin-induced activation of pyruvate dehydrogenase links mitochondrial lipid biosynthesis to TCA cycle function. J Biol Chem. 2019; 294(30): 11568-11578. doi: 10.1074/jbc.RA119.009037
6. Rattan R, Raja V, Rasool N, Elshaikh MA, Munkarah AR, Giri S. STAT3 modulates the energy metabolism of ovarian cancer cells. Gynecologic Oncology. 2018; 149: 48. doi: 10.1016/j.ygyno.2018.04.104
7. Raja V, Giri S, Sakr S, Hijaz M, Quiles R, Munkarah AR, et al. Stat3 promotes ovarian cancer by modulating the energy metabolism and develops drug resistance in patients. Cancer Res. 2018; 78 (13 Supplement): 378-378. doi: 10.1158/1538-7445.AM2018-378
8. Hijaz M, Raja V, Sakr S, Buekers TE, Morris RT, Giri S, et al. The contribution of adipocyte reservoirs towards ovarian cancer growth in time and site-specific manner. Gynecologic Oncology. 2019; 154: 67-68. doi: 10.1016/j.ygyno.2019.04.160
9. Rattan R, Raja V, Buekers TE, Hamid S, Elshaikh MA, Giri S. STAT3 promotes ovarian cancer growth and chemoresistance by modulating its energy metabolism. Gynecologic Oncology. 2019; 154: 94-95. doi: 10.1016/j.ygyno.2019.04.222
10. Rattan R, Buekers TE, Raja V, Hijaz M, Hanna RK, Hamid S, et al. Role of MCP-1 in promoting adiposity-driven ovarian cancer. Gynecologic Oncology. 2019; 154: 95. doi: 10.1016/j.ygyno.2019.04.223
11. Raja V, Giri S, Hamid S, Munkarah AR, Rattan R. Stat3 promotes ovarian cancer growth and drug resistance by modulating the energy metabolism. Clin Cancer Res. 2019; 25(22): 112. doi: 10.1158/1557-3265